small molecule

XYZAL

LEVOCETIRIZINE DIHYDROCHLORIDE

Loss of exclusivityloss of exclusivity
CompanyCHATTEM INC DBA SANOFI CONSUMER HEALTHCARE

Drug detail

Brand nameXYZAL
Active ingredientLEVOCETIRIZINE DIHYDROCHLORIDE
Strength2.5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2008
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

XYZAL patent cliff — loss of exclusivity — | CliffBio